Quality of life and wellbeing among breast cancer patients in Lahore, Pakistan

被引:3
作者
Ayub, Fiza [1 ]
Khan, Tahir Mehmood [1 ]
Baig, Mirza Rafi [2 ]
Amin, Muhammad Usman [3 ]
Tahir, Humera [4 ]
机构
[1] Univ Vet & Anim Sci UVAS, Inst Pharmaceut Sci, Lahore, Pakistan
[2] Dubai Pharm Coll Girls, Dept Clin Pharm & Pharmacotherapeut, Dubai, U Arab Emirates
[3] Abasyn Univ, Dept Pharm, Peshawar, Pakistan
[4] Ruth Pfau Coll Nutr Sci, Lahore Med & Dent Coll, Lahore, Pakistan
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
quality of Life; breast cancer; Pakistan; symptom prevalence; FACIT-B; ADVERSE DRUG-REACTIONS; FINANCIAL TOXICITY; CLINICAL-TRIALS; CHEMOTHERAPY; SURVIVORS; WOMEN; INTERVENTIONS; BURDEN; NUMBER; ADULTS;
D O I
10.3389/fonc.2023.1105411
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundBreast cancer has a high incidence rate, emphasizing the necessity of enhanced information on health-related quality of life (HrQOL) in this population of patients. The aim of this study was to identify the factors influencing the QOL experienced by patients in Pakistan. MethodsA cross-sectional study was conducted on women with breast cancer, and four instruments were used on a random sample of 130 Pakistani women: FACIT-B Version 4 questionnaire,WHO causality assessment scale, Naranjo's algorithm, and a demographic/clinical characteristics section. Data analysis included descriptive analysis, independent sample t-test, and analysis of variance (ANOVA) test. ResultsThe patients' mean age was 49.10 (standard deviation (SD) 10.89); 98.5% were married. The mean score was 18.34 for physical wellbeing (SD 5.92; interquartile range (IQR) 11), 16.33 for social/family wellbeing (SD 6.3; IQR 11.25), 13.6 for emotional wellbeing (SD 3.55; IQR 6), 17.13 for functional wellbeing (SD 3.73; IQR 6), and 24.86 for breast cancer subscale (SD 3.64; IQR 4). The study found that the age, entitlement, recurrence, marital status, salary, number of doses, duration of cancer treatment, and chemotherapy sessions were significantly related to QOL terms in the assessment of the FACIT-B scale. The WHO causality evaluation scale determined that 78.1% of the responses were "probable" and 20.1% were "possible". According to Naranjo's algorithm assessment scale, 80% of adverse drug reactions (ADRs) were "probable", whereas 18.4% were declared "possible". Chemotherapy-induced anemia was the most often reported ADR in 64.6% of patients, followed by chemotherapy-induced nausea and vomiting (61.5%). ConclusionHealthcare practitioners must acknowledge and take into account the significance of QOL in addition to therapy for breast cancer patients in order to enhance their health. The findings of this study will aid in filling gaps in current unknown knowledge and identifying sites where patients require additional assistance. Because cancer and chemotherapy clearly have a negative impact on individuals' QOL, oncologists must concentrate on strategies that help cancer patients during their sickness and treatment while also enhancing self-care and QOL. Those with cancer will benefit from emotional wellbeing and adaptation to their disease.
引用
收藏
页数:12
相关论文
共 66 条
  • [1] Aghabarari M., 2006, IRAN J NURS RES, V1, P55
  • [2] Changes in Depressive Symptoms among Older Adults with Multiple Chronic Conditions: Role of Positive and Negative Social Support
    Ahn, SangNam
    Kim, Seonghoon
    Zhang, Hongmei
    [J]. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2017, 14 (01)
  • [3] PTSD symptoms as a consequence of breast cancer diagnosis: clinical implications
    Arnaboldi, Paola
    Lucchiari, Claudio
    Santoro, Luigi
    Sangalli, Claudia
    Luini, Alberto
    Pravettoni, Gabriella
    [J]. SPRINGERPLUS, 2014, 3 : 1 - 7
  • [4] Ayub F., 2022, MALAYSIAN J PHARM, V8, P42, DOI [10.52494/EXVW6975, DOI 10.52494/EXVW6975]
  • [5] Hardiness and Optimism in Women with Breast Cancer
    Bahrami, Masoud
    Mohamadirizi, Soheila
    Mohamadirizi, Shahla
    [J]. IRANIAN JOURNAL OF NURSING AND MIDWIFERY RESEARCH, 2018, 23 (02) : 105 - 110
  • [6] Baniasadi S, 2014, IRAN J PHARM RES, V13, P291
  • [7] Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors
    Benedict, Catherine
    Fisher, Sophie
    Schapira, Lidia
    Chao, Sabrina
    Sackeyfio, Sarah
    Sullivan, Tara
    Pollom, Erqi
    Berek, Jonathan S.
    Kurian, Allison W.
    Palesh, Oxana
    [J]. PSYCHO-ONCOLOGY, 2022, 31 (01) : 9 - 20
  • [8] Health-related quality of life measurement in randomized clinical trials in surgical oncology
    Blazeby, Jane M.
    Avery, Kerry
    Sprangers, Mirjam
    Pikhart, Hynek
    Fayers, Peter
    Donovan, Jenny
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) : 3178 - 3186
  • [9] Exploring the influence of gender-role socialization and objectified body consciousness on body image disturbance in breast cancer survivors
    Boquiren, Virginia M.
    Esplen, Mary Jane
    Wong, Jiahui
    Toner, Brenda
    Warner, Ellen
    [J]. PSYCHO-ONCOLOGY, 2013, 22 (10) : 2177 - 2185
  • [10] Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
    Bottomley, Andrew
    Pe, Madeline
    Sloan, Jeff
    Basch, Ethan
    Bonnetain, Franck
    Calvert, Melanie
    Campbell, Alicyn
    Cleeland, Charles
    Cocks, Kim
    Collette, Laurence
    Dueck, Amylou C.
    Devlin, Nancy
    Flechtner, Hans-Henning
    Gotay, Carolyn
    Greimel, Eva
    Griebsch, Ingolf
    Groenvold, Mogens
    Hamel, Jean-Francois
    King, Madeleine
    Kluetz, Paul G.
    Koller, Michael
    Malone, Daniel C.
    Martinelli, Francesca
    Mitchell, Sandra A.
    Moinpour, Carol M.
    Musoro, Jammbe
    O'Connor, Daniel
    Oliver, Kathy
    Piault-Louis, Elisabeth
    Piccart, Martine
    Pimentel, Francisco L.
    Quinten, Chantal
    Reijneveld, Jaap C.
    Schuermann, Christoph
    Smith, Ashley Wilder
    Soltys, Katherine M.
    Taphoorn, Martin J. B.
    Velikova, Galina
    Coens, Corneel
    [J]. LANCET ONCOLOGY, 2016, 17 (11) : E510 - E514